CIK 0001390478
- Non-accelerated filer
- Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 646-200-5278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $716,682
- in 3 filings
Net −$716,682. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-18 | CICIC DRAGAN SVP, Chief Development Officer | Sale | −6,933 | $19.18 | $133K | 557,361 |
| 2026-01-07 | CICIC DRAGAN SVP, Chief Development Officer | Grant or award | +300,000 | 557,805 | ||
| 2025-12-03 | CICIC DRAGAN SVP, Chief Development Officer | Other disposition | −63,800 | $1.50 | $96K | 257,805 |
| 2025-01-10 | CICIC DRAGAN SVP, Chief Development Officer | Grant or award | +113,000 | 228,328 | ||
| 2025-01-10 | CICIC DRAGAN SVP, Chief Development Officer | Grant or award | +81,300 | 309,628 | ||
| 2025-01-10 | CICIC DRAGAN SVP, Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +169,500 | 169,500 | ||
| 2024-12-04 | CICIC DRAGAN SVP, Chief Development Officer | Other disposition | −8,256 | $1.13 | $9K | 115,328 |
Page 1 of 1 · 7 trades